Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Whooping Cough Test Gets CE Marking

NEW YORK (GenomeWeb) – Great Basin announced today that its Bordetella Direct assay has received CE Marking.

The PCR-based test to detect Bordetella pertussis was granted 510(k) clearance by the US Food and Drug Administration earlier this year and will now be launched commercially.

"Bordetella Direct represents a continuation of our strategy to bring to market high value tests that we expect will improve gross margins as they become a significant part of our revenues," Great Basin Cofounder and CEO Ryan Ashton said in a statement.

The Bordetella Direct test runs on the firm's molecular diagnostic platform, which also run its STEC, Group B Strep, and Toxigenic Clostridium difficile assays, and Staph Blood Culture Panel for identifying methicillin-resistant Staphylococcus aureus and other Staphylococcus species bloodstream infections.

The test was cleared by the FDA in less than two months. "The processes we put in place that resulted in a swift FDA clearance also supported our ability to quickly commercialize the Bordetella Direct test, much to the relief of many of our customers. Immediately after announcing FDA clearance, several hospitals contacted us requesting immediate access to the assay in order to respond to the testing demands from local pertussis outbreaks," Ashton added.

While some labs have adopted in-house molecular diagnostic testing for Bordetella, commercial options are "a choice of expensive panels that test for a wide variety of unrelated respiratory issues or more cost-effective, but labor-intensive stand-alone tests," according to Sandra Nielsen, senior vice president of sales and marketing for Great Basin. "We believe that our solution offers the best of all worlds — an easy-to-use, cost-effective test that provides an answer in less than two hours." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.